Warning Cookies are used on this site to provide the best user experience. If you continue, we assume that you agree to receive cookies from this site. OK

Gynaecology and Obstetrics Outpatients - Penoxal study

29/08/2018
by Admin Penoxal

Penoxal Study

(Gynaecology and Obstetrics Outpatients of MUDr. Zdeněk Vocásek, Jihoslovanská 465, Vrchlabí) 

Total number of 52 patients (precancerosis of cervix) – 30 of those presenting with ASC-US (Atypical Squamous Cells of Undetermined Significance) and 22 patients with LSIL (Low-grade Squamous Intraepithelial Lesion), they had used Penoxal for 4 months in a dose of 100 mg 1–0–1.   

Follow-up cytology results:
 

1st ASC-US group (Atypical Squamous Cells of Undetermined Significance)

30 patients in total – follow-up cytology in 4 months

- Negative: 19

- LSIL: 2

- ASC-US: 5

- HSIL followed by cervical conisation: 2

- 2 patients failed to attend the follow-up sampling

 

2nd LSIL group – (Low-grade Squamous Intraepithelial Lesion, precancerosis of cervix)

22 patients in total – follow-up cytology in 4 months

- Negative: 8

- LSIL: 8

- ASC-US: 2

- HSIL followed by cervical conisation: 2

- 2 patients failed to attend the follow-up sampling

 

Patient sample: 

They were female patients presenting with cellular changes on cervical cytology that fall under dysplastic cellular changes and require continuing health care. There were two types of changes – ASC-US and LSIL. 

 

Study results: 

We investigated whether Penoxal could promote the function of the immune system and lead to a regression found on cytology. 

 

Effects of Penoxal on changes to ASC-US:

2/3 of the sample showed negative results after the use of preparation, the half of the remaining third showed same results, less than 7% had other dysplastic changes requiring continuing health care, and the changes deteriorated in 7% of patients who needed a surgical intervention. Two patients had failed to attend the follow-up smear.

 

Effects of Penoxal on changes to LSIL:

In 1/3 of patients (36.4%) the changes had disappeared completely after the use of Penoxal, one third of cases (36.4%) showed no changes, 9% of patients demonstrated a different type of mild dysplasia requiring continuing health care, and changes had become worse in 9% of patients who showed precancerosis and required a surgical intervention.  In two cases the patients failed to attend the follow-up smear. 

 

Study conclusions after 4 months of Penoxal use

The overall evaluation suggests that taking Penoxal for four months is more beneficial for female patients presenting with ASC-US cellular changes, because up to 2/3 of the cases demonstrated a complete recovery when compared to female patients presenting with LSIL dysplastic changes, where only 1/3 of patients had negative findings. Both groups demonstrated deterioration to the same extent. Overall, we may propose that over a half of follow-up smear tests (51.9%) were negative in those who were taking Penoxal for 4 months due to dysplastic changes found on cytology. 

 

The study was conducted by MUDr. Eva Zahradníková who represents the clinic of MUDr. Zdeněk Vocásek (Senior Consultant).

 

In Vrchlabí, 13/8/2018

Comments

No posts found

New post

Your name will appear next to your review or comment, visible to everyone. We (Sonowa Sp.z o.o. ) also save your IP address as a security precaution, but in can only be viewed by our staff. It will remain in our system until you withdraw your consent. If you’d like to have your personal data removed, send an email to info@penoxal.com.

If you believe that your personal data has been misused, you have the right to lodge a complaint with a supervisory authority. We’re obliged by EU General Data Protection Regulation to let you know about this right; we don’t actually intend to misuse your data.